Details

Autor(en) / Beteiligte

• Ginzler, Ellen M
• Dooley, Mary Anne
• Aranow, Cynthia
• Kim, Mimi Y
• Buyon, Jill
• Merrill, Joan T
• Petri, Michelle
• Gilkeson, Gary S
• Wallace, Daniel J
• Weisman, Michael H
• Appel, Gerald B

Titel

Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis

Ist Teil von

• The New England journal of medicine, 2005-11, Vol.353 (21), p.2219-2228

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2005

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• This 24-week randomized, open-label, noninferiority trial compared oral mycophenolate mofetil with monthly intravenous cyclophosphamide as induction therapy for active lupus nephritis. Mycophenolate mofetil appeared more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis, with a more favorable safety profile. Mycophenolate mofetil appeared to be more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis, with a more favorable safety profile. Intravenous cyclophosphamide has been the standard of care for treating severe lupus glomerulonephritis 1 ; however, its use is limited by potentially severe toxic effects including bone marrow suppression, hemorrhagic cystitis, opportunistic infections, malignant diseases, and premature gonadal failure. 2 Clinical trials of treatment with intermittent intravenous cyclophosphamide combined with corticosteroids show greater long-term renal survival but not overall survival, as compared with treatment with corticosteroids alone. 3 – 6 Furthermore, failure to achieve remission, which is associated with an increased rate of progression to renal failure, is reported in 18 to 57 percent of patients who received cyclophosphamide. 7 – 10 Mycophenolate mofetil, an immunosuppressive . . .